yf_tkr_UTHR · 2026-08-25
United Therapeutics (UTHR) is back in focus after the FDA accepted its New Drug Application for ralinepag, an investigational once daily oral prostacyclin for pulmonary arterial hypertension, with a target action date set for June 24, 2027. See our latest analysis for United Therapeutics. The ralinepag filing comes after a strong run for United Therapeutics, with the stock delivering a 67.95% total shareholder return over the past year even as the 90 day share price return declined 11.33%...
Read the original at yf_tkr_UTHR ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。